Ulisse Biomed, a company listed on Euronext Growth Milan and active in the fields of diagnostics, theranostics, and therapeutics, has entered into an equity financing investment agreement of up to 10 million euros with the U.S. family office Global Corporate Finance.

LEXIA advised Ulisse Biomed on the transaction with a team coordinated by partners Francesco Dagnino and Andrea Massimo Maroni (pictured, from left to right), assisted by associates Marco Pontiggia and Gabriel Zurlo Sconosciuto. For the execution of the agreement, the firm also assisted Ulisse Biomed in the adoption of the capital increase resolutions by the Board of Directors, excluding pre-emptive rights, and in the preparation of the related corporate and regulatory documentation.

The details

The transaction requires the investor to subscribe, at the request of Ulisse Biomed, to one or more tranches of a reserved capital increase. The agreement also provides for the free allocation of warrants to the investor, exercisable within five years at a predetermined strike price, significantly higher than current market values. An additional capital increase has also been approved to support the potential exercise of the warrants, amounting to approximately 5 million euros.

The transaction allows Ulisse Biomed to access an alternative form of financing to traditional channels, characterized by flexibility, rapid execution, and the ability to adjust capital contributions based on the company’s strategic and operational needs. The raised funds will be used for the implementation of the industrial plan, strengthening research and development activities, and potentially carrying out extraordinary transactions.

Full article on Legalcommunity >